Enter at least 3 characters
Home > Press release

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Text email send
Authorize the processing of personal data
Data from two randomised, double-blind, parallel-group, active-controlled studies on the efficacy and safety of single-inhaler triple therapy in adult patients with uncontrolled asthma is published...
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
Paolo Chiesi appointed Honorary Doctor at Karolinska Institutet
Chiesi Group receives the EURORDIS Black Pearl Award for innovation in the field of Rare Disease.
Chiesi Farmaceutici changes statute to become “Benefit Corporation”.
COPD, a disease still underestimated by Europeans: absence of perceived risk, according to Eurisko survey.
Chiesi Acquires NHCO Nutrition® SAS and strengthens its OTC portfolio in France.
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa)
Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)
Chiesi Group receives the European Marketing Authorisation for Lamzede®▼(velmanase alfa)
Chiesi hosts groundbreaking ceremony for the Group’s future Headquarters
New study published in The Lancet shows Trimbow® (beclometasone/formoterol/glycopyrronium) superiority over Ultibro® Breezhaler® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
Chiesi Group confirmed Top Employer 2018 in Italy and Europe
Chiesi Group receives positive opinion from CHMP for Lamzede® (velmanase alfa), the first therapy for Alpha-Mannosidosis
The Chiesi Group is one of the 8 Italian companies invited by Macron to the French International Summit in Versailles
Chiesi is the first Italian pharmaceutical Company for investments in Research and Development
TRIBUTE study shows superiority of Chiesi's Trimbow® (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)
Trimbow® is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
Glybera▼ (alipogene tiparvovec) in Europe
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma
Chiesi Farmaceutici is the first company to submit a marketing authorisation application to the European Medicine Agency for a Triple Combination for the treatment of COPD
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study
Patients with COPD benefit from the Chiesi extrafine fixed triple combination ICS/LABA/LAMA: highly effective and easy to use.
An extrafine ICS/LABA combination decreases COPD exacerbations more than
Chiesi To Acquire 3 Hospital Products
80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015
Europe approves Holoclar®, the first stem cell—based medicinal product